Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study.

oral anticoagulant drugs oral antiplatelet drugs primary health care secondary stroke prevention

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
28 Sep 2021
Historique:
received: 01 08 2021
revised: 12 09 2021
accepted: 21 09 2021
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 14 10 2021
Statut: epublish

Résumé

The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors. From all patients in LIPIDOGRAM2015 Study ( 165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were associated with antiplatelet treatment ( In Poland drugs and lifestyle modification for secondary stroke prevention are not commonly adhered to. Educational programmes for physicians and patients should be developed to improve application of effective secondary prevention of stroke.

Sections du résumé

BACKGROUND BACKGROUND
The purpose of the study was to evaluate secondary stroke prevention in Poland and its association with sociodemographic factors, place of residence, and concomitant cardiovascular risk factors.
MATERIAL AND METHODS METHODS
From all patients in LIPIDOGRAM2015 Study (
RESULTS RESULTS
165 subjects (61.6%) used at least one preventive medication. Oral antiplatelet and anticoagulation agents were used by 116 (43.3%) and 70 (26.1%) patients, respectively. Only 157 (58.6%) participants used lipid-lowering drugs, and 205 (76.5%) were treated with antihypertensive drugs. Coronary heart disease (CHD) and dyslipidaemia were associated with antiplatelet treatment (
CONCLUSIONS CONCLUSIONS
In Poland drugs and lifestyle modification for secondary stroke prevention are not commonly adhered to. Educational programmes for physicians and patients should be developed to improve application of effective secondary prevention of stroke.

Identifiants

pubmed: 34640490
pii: jcm10194472
doi: 10.3390/jcm10194472
pmc: PMC8509736
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Valeant Pharmaceuticals International
ID : Educational grant

Références

Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
J Am Coll Nutr. 2015;34(5):408-15
pubmed: 25826615
Stroke. 2010 Feb;41(2):397-401
pubmed: 20075360
J Am Heart Assoc. 2018 May 17;7(11):
pubmed: 29773578
Neurol Neurochir Pol. 2017 Sep - Oct;51(5):382-387
pubmed: 28756016
Neurol Neurochir Pol. 2018 Mar;52(2):252-262
pubmed: 29221869
Arch Med Sci. 2020 Mar 02;16(2):237-252
pubmed: 32190133
BMC Cardiovasc Disord. 2012 Oct 31;12:98
pubmed: 23114009
Arch Neurol. 1992 Aug;49(8):857-63
pubmed: 1524519
N Engl J Med. 2018 Dec 20;379(25):2429-2437
pubmed: 30575491
Arch Med Sci. 2019 Mar;15(2):385-392
pubmed: 30899291
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
Pharmacol Res. 2017 Aug;122:105-117
pubmed: 28602797
Comput Math Methods Med. 2020 Jun 1;2020:3217356
pubmed: 32565878
Am Fam Physician. 2017 Oct 1;96(7):436-440
pubmed: 29094912
N Engl J Med. 2013 Apr 4;368(14):1279-90
pubmed: 23432189
Med Clin North Am. 2019 Mar;103(2):295-308
pubmed: 30704682
Stroke. 1982 May-Jun;13(3):290-5
pubmed: 7080120
Stroke. 2021 Jul;52(7):e364-e467
pubmed: 34024117
BMC Neurol. 2017 Feb 6;17(1):24
pubmed: 28166784
PLoS One. 2020 Mar 2;15(3):e0226766
pubmed: 32119685
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
J Stroke Cerebrovasc Dis. 2017 Dec;26(12):2806-2813
pubmed: 28823491
Lancet Neurol. 2019 May;18(5):439-458
pubmed: 30871944
Int J Epidemiol. 2019 Dec 1;48(6):1824-1838
pubmed: 31056682
Vasc Health Risk Manag. 2010 Oct 21;6:943-56
pubmed: 21057579
Atheroscler Suppl. 2020 Dec;42:e15-e24
pubmed: 33589219
Stroke. 2010 Jul;41(7):1338-42
pubmed: 20522818
Atherosclerosis. 2020 Nov;312:16-22
pubmed: 32947222
Lancet. 2001 Sep 29;358(9287):1033-41
pubmed: 11589932
Cardiovasc Res. 2019 Mar 1;115(3):e26-e31
pubmed: 30605511
Neurol Neurochir Pol. 2014;48(2):85-90
pubmed: 24821632
Circ Cardiovasc Qual Outcomes. 2018 Jan;11(1):e003228
pubmed: 29321134

Auteurs

Beata Labuz-Roszak (B)

Department of Neurology, Institute of Medical Sciences, University of Opole, 45-052 Opole, Poland.

Maciej Banach (M)

Polish Mothers Memorial Hospital Research Institute, 93-338 Lodz, Poland.
Department of Preventive Cardiology and Lipidology, Medical University of Lodz, 93-338 Lodz, Poland.
Cardiovascular Research Centre, University of Zielona Gora, 65-046 Zielona Gora, Poland.

Michal Skrzypek (M)

Department of Biostatistics, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, 41-902 Bytom, Poland.

Adam Windak (A)

Department of Family Medicine, Jagiellonian University Medical College, 31-061 Krakow, Poland.

Tomasz Tomasik (T)

Department of Family Medicine, Jagiellonian University Medical College, 31-061 Krakow, Poland.

Miroslaw Mastej (M)

Mastej Medical Center, 38-200 Jasło, Poland.

Maciej Tomaszewski (M)

Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PT, UK.

Dimitri P Mikhailidis (DP)

Department of Clinical Biochemistry, Royal Free Hospital, University College London, London NW3 2QG, UK.

Peter P Toth (PP)

Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
CGH Medical Center, Sterling, IL 61081, USA.

Alberico Catapano (A)

Department of Pharmacological Sciences, University of Milano and Multimedica IRCCS, 20099 Milano, Italy.

Kausik K Ray (KK)

Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, Imperial College, Kensington, London W6 8RP, UK.

George Howard (G)

Department of Biostatistics, School of Public Health of Alabama at Birmingham, Birmingham B15 2TT, UK.

Gregory Y H Lip (GYH)

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool L14 3PE, UK.
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark.

Fadi J Charchar (FJ)

School of Health and Life Sciences, Federation University Australia, Ballarat, VIC 3350, Australia.

Naveed Sattar (N)

Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow G12 8TA, UK.

Bryan Williams (B)

NIHR University College London Biomedical Research Centre, University College London and University College London Hospitals NHS Foundation Trust, London NW1 2BU, UK.

Thomas M MacDonald (TM)

MEMO Research, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.

Peter Penson (P)

School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L2 2QP, UK.
Liverpool Centre for Cardiovascular Science, Liverpool L69 7TX, UK.

Jacek J Jozwiak (JJ)

Department of Family Medicine and Public Health, Institute of Medical Sciences, University of Opole, 45-052 Opole, Poland.

Classifications MeSH